| Mr Syed Zafar Salik, MD | |
|
363 S. Main Street, Suite 345, Decatur, IL 62523-1412 | |
| (217) 791-6703 | |
| (217) 791-6976 |
| Full Name | Mr Syed Zafar Salik |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 39 Years |
| Location | 363 S. Main Street, Decatur, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265408694 | NPI | - | NPPES |
| 036.122223 | Medicaid | IL | |
| 02595233 | Medicaid | NY |
| Facility Name | Location | Facility Type |
|---|---|---|
| Decatur Memorial Hospital | Decatur, IL | Hospital |
| Entity Name | Cook County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588612832 PECOS PAC ID: 2860398088 Enrollment ID: O20031209000747 |
News Archive
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
As Congress considers both the FY11 and FY12 budgets, the Kaiser Daily Global Health Policy Report's Jaclyn Schiff spoke to Adam Wexler, a senior policy analyst for global health policy at the Kaiser Family Foundation, about the potential implications for global health funding.
One in five people with depression have suicidal thoughts despite treatment with antidepressants. This is shown by a new study from iPSYCH. The results can be used to examine whether more targeted treatment could be provided for patients where medication does not have a sufficient effect.
› Verified 6 days ago
| Entity Name | Pavilion Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518930619 PECOS PAC ID: 7911043740 Enrollment ID: O20091008000646 |
News Archive
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
As Congress considers both the FY11 and FY12 budgets, the Kaiser Daily Global Health Policy Report's Jaclyn Schiff spoke to Adam Wexler, a senior policy analyst for global health policy at the Kaiser Family Foundation, about the potential implications for global health funding.
One in five people with depression have suicidal thoughts despite treatment with antidepressants. This is shown by a new study from iPSYCH. The results can be used to examine whether more targeted treatment could be provided for patients where medication does not have a sufficient effect.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Syed Zafar Salik, MD 231 Raptor Court, Forsyth, IL 62535-9674 Ph: (217) 791-6703 | Mr Syed Zafar Salik, MD 363 S. Main Street, Suite 345, Decatur, IL 62523-1412 Ph: (217) 791-6703 |
News Archive
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
As Congress considers both the FY11 and FY12 budgets, the Kaiser Daily Global Health Policy Report's Jaclyn Schiff spoke to Adam Wexler, a senior policy analyst for global health policy at the Kaiser Family Foundation, about the potential implications for global health funding.
One in five people with depression have suicidal thoughts despite treatment with antidepressants. This is shown by a new study from iPSYCH. The results can be used to examine whether more targeted treatment could be provided for patients where medication does not have a sufficient effect.
› Verified 6 days ago
Dr. Jeanne Marie Kairouz, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1770 E Lake Shore Dr Ste 105, Decatur, IL 62521 Phone: 217-422-6100 | |
Dr. Stephen R Goetter, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 304 W Hay St, Ste 312, Decatur, IL 62526 Phone: 217-876-5600 Fax: 217-876-5664 | |
Dr. Prameeta Jha, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2300 N Edward St Ste 3200, Decatur, IL 62526 Phone: 217-876-3660 Fax: 217-876-3665 | |
David W Baumberger, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 304 W Hay St, Ste 312, Decatur, IL 62526 Phone: 217-876-5600 Fax: 217-876-5664 | |
Dr. Ahmad H Ahmad, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1770 E Lake Shore Dr, Suite 201, Decatur, IL 62521 Phone: 217-428-7921 Fax: 217-428-7931 | |
Nadal M Aker, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2300 N Edward St, Suite 2400, Decatur, IL 62526 Phone: 217-876-2400 Fax: 217-876-2405 | |
Omar Mohammad Al-heeti, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 102 W Kenwood Ave, Decatur, IL 62526 Phone: 217-545-8000 |